Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions

PHASE3CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

December 23, 2022

Study Completion Date

December 23, 2022

Conditions
Endoscopic Mucosal ResectionColonic NeoplasmsTherapeutic IrrigationTreatment Outcome
Interventions
COMBINATION_PRODUCT

Mucopolysaccharide saline solution 0.9%

Injectable solution designed for submucosal elevation in endoscopic mucosal resection. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.

COMBINATION_PRODUCT

Saline solution 0.9%

Control injectable solution composed of saline 0.9 %. Administered via submucosal injection prior to polyp resection, adding 1% indigo carmine before administration.

Trial Locations (1)

04009

Hospital Universitario Torrecárdenas, Almería

All Listed Sponsors
collaborator

Hospital Torrecárdenas, Almería, Spain

UNKNOWN

collaborator

Hospital Poniente, El Ejido, Almería, Spain

UNKNOWN

collaborator

Hospital Virgen del Rocío, Seville, Spain

UNKNOWN

collaborator

Hospital de Baza, Granada, Spain

UNKNOWN

collaborator

Hospital Virgen de Valme, Seville, Spain

UNKNOWN

collaborator

Quirónsalud, Málaga, Spain

UNKNOWN

lead

Nakafarma S.L.

INDUSTRY

NCT06910514 - Efficacy and Safety of a Solution for Endoscopic Mucosal Resection of Colonic Lesions | Biotech Hunter | Biotech Hunter